Claudin18.2-Specific CAR T Cells in Gastrointestinal Cancers: Phase I Trial Interim Results

Researchers reported the interim analysis results of an ongoing, open-label, single-arm, Phase I clinical trial of CLDN18.2-targeted CAR T cells in patients with previously treated, CLDN18.2-positive digestive system cancers.